Cargando…

Bergamottin and PAP-1 Induced ACE2 Degradation to Alleviate Infection of SARS-CoV-2

Angiotensin-converting enzyme 2 (ACE2), a functional receptor for SARS-CoV, now appears likely to mediate 2019-nCoV entry into human cells. However, inhibitors such as PAP-1 and bergamottin have been discovered; both of them can preferentially bind to ACE2, prevent RBD Spike S protein from binding t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mengjia, Zhang, Yongzheng, Zeb, Amir, Wu, Yang, Cheng, Lufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604380/ https://www.ncbi.nlm.nih.gov/pubmed/36293419 http://dx.doi.org/10.3390/ijms232012565

Ejemplares similares

Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters
por: Zhou, Minmin, et al.
Publicado: (2022)

SARS-CoV-2 down-regulates ACE2 through lysosomal degradation
por: Lu, Yi, et al.
Publicado: (2022)

GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus
por: Yeh, Hsin, et al.
Publicado: (2022)

An ace model for SARS-CoV-2 infection
por: Major, Jack, et al.
Publicado: (2020)

Soluble ACE2 in SARS-CoV-2 infection
por: Allison, Susan
Publicado: (2021)

ACE2: the molecular doorway to SARS-CoV-2
por: Medina-Enríquez, Miriam Marlene, et al.
Publicado: (2020)

Fish ACE2 is not susceptible to SARS-CoV-2
por: Xie, Shi-Zhe, et al.
Publicado: (2022)

The flexibility of ACE2 in the context of SARS-CoV-2 infection
por: Barros, E. P., et al.
Publicado: (2020)

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
por: Vitiello, A., et al.
Publicado: (2021)

Endocrine Significance of SARS-CoV-2’s Reliance on ACE2
por: Lazartigues, Eric, et al.
Publicado: (2020)

The flexibility of ACE2 in the context of SARS-CoV-2 infection
por: Barros, Emilia P., et al.
Publicado: (2021)

Oral cancer and ACE2 receptor of SARS-CoV-2
por: Martelli-Júnior, Hercílio, et al.
Publicado: (2020)

Endocrine significance of SARS-CoV-2’s Reliance on ACE2
por: Chappell, Mark C
Publicado: (2020)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

The glycosylation in SARS-CoV-2 and its receptor ACE2
por: Gong, Yanqiu, et al.
Publicado: (2021)

ACE2-independent infection of T lymphocytes by SARS-CoV-2
por: Shen, Xu-Rui, et al.
Publicado: (2022)

ACE2-Independent Alternative Receptors for SARS-CoV-2
por: Lim, Suhyeon, et al.
Publicado: (2022)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
por: Anand, Sai Priya, et al.
Publicado: (2020)

Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells
por: Hattori, Takanari, et al.
Publicado: (2022)

Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses
por: Su, Siyuan, et al.
Publicado: (2021)

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
por: Lu, Mengjia, et al.
Publicado: (2023)

Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2
por: Hatmal, Ma’mon M., et al.
Publicado: (2020)

The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection
por: Schieffer, Elisabeth, et al.
Publicado: (2022)

Dynamics of the ACE2–SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms
por: Ali, Amanat, et al.
Publicado: (2020)

Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?
por: Nguyen, Hoang Linh, et al.
Publicado: (2020)

Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2
por: Xie, Yixin, et al.
Publicado: (2020)

Structural dynamic changes in the SARS-CoV and SARS-CoV-2 S spike assemblies upon ACE2 activation
por: Chen, Chengbo, et al.
Publicado: (2022)

Distinct Differences in the Interactions of Receptor Binding Domains of SARS-CoV-2 and SARS-CoV with Human ACE2
por: Acharya, Atanu, et al.
Publicado: (2021)

Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
por: Shukla, Nidhi, et al.
Publicado: (2021)

Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2
por: Wu, Lili, et al.
Publicado: (2020)

Relation of ACE2 with co-morbidity factors in SARS-CoV-2 pathogenicity
por: Santra, Dipannita, et al.
Publicado: (2023)

Bergamottin alleviates LPS-induced acute lung injury by inducing SIRT1 and suppressing NF-κB
por: An, Ning, et al.
Publicado: (2021)

ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
por: Saponaro, Federica, et al.
Publicado: (2020)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

ACE2: The Major Cell Entry Receptor for SARS-CoV-2
por: Scialo, Filippo, et al.
Publicado: (2020)

Sars-CoV-2 and black population: ACE2 as shield or blade?
por: Vinciguerra, Mattia, et al.
Publicado: (2020)

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
por: Alhenc-Gelas, Francois, et al.
Publicado: (2020)

Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
por: Li, Yanwei, et al.
Publicado: (2020)

Role of SARS-CoV-2 and ACE2 variations in COVID-19
por: Antony, Priya, et al.
Publicado: (2021)

Cross-species recognition of SARS-CoV-2 to bat ACE2
por: Liu, Kefang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ugh03a6p3smqfl2scj1ln9etbt